• Registration Decision RD2021-01, Trifludimoxazin, Vulcarus and Voraxor
• Proposed Registration Decision PRD2020-09, Fluxapyroxad and Xzemplar
• Proposed Registration Decision PRD2021-09, Flutianil and GATTEN
• Proposed Registration Decision PRD2020-17, Imazapyr, Habitat Aqua
• Proposed Registration Decision PRD2022-08, cis-Jasmone and Trunemco